Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Company intends to collaborate with government initiatives, Long COVID patient organizations, and major healthcare providers to...
Tevogen ("Tevogen Bio Holdings Inc." or "Company") (NASDAQ: TVGN), today announced significant progress in the ...
Tevogen ("Tevogen Bio Holdings Inc." or "Company") (NASDAQ:TVGN), today highlights emerging scientific evidence...
Tevogen ("Tevogen Bio Holdings Inc." or "Company") (NASDAQ: TVGN), today shared asset value and potential forec...
The risk adjusted Net Present Value (rNPV) for TVGN 930 is estimated to exceed ~$250 million in the US alone.Covering five rare...
D. Boral Capital analyst Jason Kolbert maintains Tevogen Bio Holdings (NASDAQ:TVGN) with a Buy and maintains $10 price target.
Tevogen ("Tevogen Bio Holdings Inc." or "Company") (NASDAQ:TVGN), today highlighted the continuing need for SAR...
Tevogen ("Tevogen Bio Holdings Inc." or "Company") (NASDAQ:TVGN), today announced an update on institutional ow...
